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Patients with thyroid orbitopathy commonly present 
with soft tissue features of infiltrative disease, such as 
eyelid retraction and swelling, conjunctival injection, ex-
ophthalmos, and restrictive myopathy; however, in severe 
cases potentially blinding conditions, such as corneal 
ulcer and optic neuropathy, may manifest. Dysthyroid 
optic neuropathy (DON) occurs in approximately 5% of 
patients with thyroid orbitopathy [1]. DON patients may be 
asymptomatic with good vision, but it is best assessed by 
decreased visual acuity, reduced color vision, visual field 
defects, or afferent pupillary defects [2]. 
Most cases of DON are considered to occur as the result 
of optic nerve compression at the orbital apex via expanded 
intraorbital contents, particularly the extraocular muscles 
[1,3-9]. The increases in orbital fibroblast synthesis of hyal-
uronan result in an accumulation of glycosaminoglycan in 
the retrobulbar tissues [10]. The expansion of retrobulbar 
tissues in an area of fixed volume increases pressure at the 
orbital apex, which may inhibit axoplasmic flow [5] or in-
duce optic nerve ischemia [8,11,12].
Treatments widely accepted for patients with DON in-
clude systemic corticosteroids, orbital radiation therapy 
and orbital decompression. Pulse methylprednisolone 
therapy may provide a rapid means for achieving maximal 
visual recovery, which can be sustained using a tapering 
regimen of oral corticosteroids and orbital irradiation [13]. 
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Purpose: To report the clinical data and visual outcomes after treatment of patients with dysthyroid optic neu-
ropathy (DON).
Methods: We retrospectively reviewed the medical records and orbital images of 40 patients (65 eyes) with 
DON and analyzed the visual outcomes after treatment with intravenous steroids pulse therapy, radiotherapy 
and orbital decompression.
Results: The study included 21 men and 19 women, with 10 (25%) being diabetic patients. Visual field test 
results revealed defects in 88.7% of DON eyes; afferent pupillary defects in 63.2%; reduced color vision in 
78.5%; and abnormal visual evoked potentials in 84%. Orbital imaging showed moderate to severe apical 
crowding in 95% of the orbits and intracranial fat prolapse in 24.2%. Median best corrected visual acuity im-
proved from 0.4 to 1.0 after one year of treatment (p < 0.001). We noted more improvement in vision with the 
use of decompressive surgery than with non-surgical methods (p < 0.05). Recurrences occurred in 7 patients 
who had not received orbital radiotherapy.
Conclusions: Visual field defects and apical crowding seen on orbital imaging were the most sensitive indica-
tors for the detection of DON. Treatment with intravenous steroids pulse therapy, radiotherapy and orbital de-
compression effectively improved visual outcomes in cases of DON.
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Thyroid orbitopathy is characterized by an autoimmune 
active inflammation period of 6 to 18 months, during 
which, treatment with high-dose intravenous corticoste-
roids may effectively inhibit inflammatory processes and 
improve visual prognosis [14]. Radiation therapy is also 
useful in reducing active inflammation with optic nerve 
compression [5,7,10,15,16]. However, the efficacy of using 
radiation therapy alone must be determined, as the litera-
ture only reports on its utilization in combination with ste-
roid therapy. Some authors have been unable to detect any 
beneficial effects of radiation therapy when used by itself 
[17,18]. Bony orbital decompression is considered to be the 
most effective treatment for DON, in that it provides rapid 
and persistent relief of apical compression [19].
As there remains controversy over the assessment and 
management of DON [20], it has proven difficult for clini-
cians to make an accurate diagnosis and recommend a par-
ticular measure to halt the progression of optic neuropathy 
and restore visual acuity. Asians have shown evidence of 
less severe orbitopathy than Caucasians, but a rather nar-
row orbital apex may result in earlier compressive features 
[2]. The principal objective of this study is to evaluate clin-
ical pictures and treatment outcomes in Korean patients 
with DON. We have reviewed the clinical data and orbital 
imaging findings of 40 patients with DON who presented 
to the Samsung Medical Center, and evaluated the visual 
outcomes after treatment with intravenous steroids, orbital 
radiation therapy and/or orbital decompression. 
Materials and Methods
We reviewed the records of patients with DON at the 
Samsung Medical Center from April 1995 to August 2007. 
Optic neuropathy was diagnosed by one of the following: 
decreased visual acuity, reduced color vision, visual field 
defects or relative afferent pupillary defects. 
We investigated clinical features, including demographic 
characteristics, past medical history, thyroid status, as well 
as its relationship to thyroid orbitopathy. Visual functions 
were evaluated for best corrected visual acuity, color vi-
sion (Ishihara color plates), relative afferent pupillary de-
fect, visual fields (Goldmann or static automated perimetry 
using the central 30-2 full threshold program), and visual 
evoked potentials (VEPs). An analysis of orbital imaging 
(computed tomography or magnetic resonance imaging) 
was conducted to document the compression of the optic 
nerve at the orbital apex and orbital volume expansion. We 
evaluated visual outcomes and recurrence after treatment.
Orbital imaging parameters included optic nerve crowd-
ing, muscle index, and intracranial fat prolapse. Optic 
nerve crowding induced by enlarged extraocular muscles 
at the orbital apex was assessed on the coronal images us-
ing the grading scale described by Nugent et al. [21]. Grade 
0 reflects no effacement of the perineural fat planes due 
to enlarged extraocular muscles, grade 1 (mild) reflects 
1% to 25% effacement, grade 2 (moderate) reflects 25% to 
50% effacement and grade 3 (severe) reflects effacement 
greater than 50%. Muscle indices (MIs) were calculated 
in accordance with the method described by Barrett et al. 
[22]. Measurements were obtained from coronal scans at a 
point halfway between the posterior globe and the orbital 
apex. The transverse dimensions of the horizontal muscle 
groups (medial and lateral recti) and the orbital width 
were measured along a horizontal line through the optic 
nerve. The horizontal MI was expressed as the percentage 
of orbital width occupied by the medial and lateral rectus 
muscles. The vertical MI was expressed as the percentage 
of the height of the orbit occupied by the inferior rectus 
and the superior muscle group. The greater of these two 
values was taken as the final muscle index. Intracranial fat 
prolapse was determined using Birchall et al.’s method [23]. 
The extent of posterior orbital fat was defined relative to 
the boundaries of the superior ophthalmic fissure, which 
were defined on the axial images obtained, parallel to the 
Reid baseline. The lateral margin of the superior ophthal-
mic fissure was defined as the most medial portion of the 
inner border of the sphenoid wing. The medial margin was 
identified as the anterior border of the groove in the sphe-
noid body formed by the terminal intracavernous portion 
of the internal carotid artery. Intracranial fat prolapse was 
considered to be present if fat was detected 2 mm or more 
posterior to this line.
Treatment options consisted of one of the following three 
modalities: intravenous methylprednisolone pulse (IVMP) 
therapy, orbital radiation therapy and orbital decompres-
sion (bony removal of the medial and inferior wall). 
Methylprednisolone (250 mg) was administered every six 
hours via intravenous infusion for three consecutive days. 
Patients failing IVMP therapy underwent orbital decom-
pression via transcaruncular or transnasal endoscopic ap-
proaches. After the completion of intravenous corticoste-
roids or decompression surgery, 80 mg of prednisone was 
orally administered for seven days and tapered at 10 mg a 
week until a dose of 20 mg was reached, then tapered by 5 
mg every week. Orbital radiation therapy was instituted in 
patients whose optic neuropathy recurred or when orbital 
inflammation persisted, despite treatment with corticoste-
roids or orbital decompression. The orbital radiation dose 
was 20 Gy in 10 fractions over two weeks.
Descriptive statistics were utilized in order to describe 
the basic features of the data in our study. We assessed 
changes in visual acuity after treatment using the paired 
t-test. An independent t-test and the Mann-Whitney test 
were utilized in order to compare visual acuity changes in 
the orbital decompression group versus those in the non-
decompression group. Decimal visual acuity data were 
converted logarithmically to the minimum angle of resolu-
tion (logMAR) equivalents for statistical analysis. Statisti-75
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cal significance was indicated when p < 0.05.
Results
Sixty-five eyes of 40 patients (21 male, 19 female) were 
included in this study. Twenty-five patients had bilateral 
DON and 15 patients had unilateral optic neuropathy. The 
average age at the time of diagnosis was 50.0 years (range, 
20 to 74 years). We noted no age difference between sexes. 
It required a median 5.5 months (range, 0 days to 120 
months) for the patients to develop DON after the onset of 
thyroid eye disease, and the interval between subjective 
symptoms of DON and the first therapy was a median of 2 
months (range, 7 days to 11 months). The median follow-up 
time after the initial treatment was 18 months (range, 5 to 
120 months).
The results of the thyroid function test showed that 32 
patients (80%) were euthyroid, 4 (10%) were hyperthyroid 
and 4 (10%) were hypothyroid. Ten patients (25%) also had 
type II diabetes mellitus. 
The median best corrected visual acuity of the 65 eyes 
with DON at presentation was 0.4 (range, hand motion 
to 1.0) (Fig. 1). The visual field was abnormal in 55 eyes 
(88.7%) out of 62 eyes for which data were available. Color 
vision was abnormal in 51 eyes (78.5%) out of 65 ey es 
with DON, whose mean Ishihara color plate values were 
6.7 (range, 0 to 15). Relative afferent pupillary defects were 
noted in 24 patients (63.2%) out of the 38 tested. VEPs 
were assessed in 30 patients. Of 50 eyes with DON, the 
VEPs were determined to be abnormal in 42 eyes (84.0%), 
with 37 having delayed latency and 21 with decreased am-
plitude. The results of fundus examination were obtained 
in 55 DON eyes: normal in 29 eyes (52.7%), disc edema in 
23 eyes (41.8%), and optic atrophy in 3 eyes (5.5%).
We were able to review the orbital imaging of 62 orbits 
with DON (Table 1). Grade 3 (severe) optic nerve crowding 
was noted in 32 (51.7%) orbits. No orbits with DON evi-
denced less than grade 1 apical crowding. A muscle index 
of 67% or greater was noted in 28 eyes (45.2%). None of 
the DON orbits had muscle indices of less than 50%. Intra-
cranial fat prolapse was noted in 15 orbits (24.2%).
Treatment for DON consisted of a combination of three 
modalities (Table 2). IVMP therapy was utilized in the ini-
tial management of 39 patients with DON: 6 patients were 
treated successfully by corticosteroids alone; 16 patients 
who failed to improve on corticosteroids subsequently re-
ceived orbital decompression; and 25 patients were treated 
with radiation therapy. One untreated patient had normal 
visual acuity, but also had an abnormal visual field and a 
color perception defect. She refused any treatment, and her 
visual field and color vision returned to normal without 
treatment after six months.
Average visual acuity improved from a median of 0.4 to 
0.7 one month after the initial treatment, no change was 
seen in the subsequent five months, visual acuity reached 
0.9 at 12 months and 1.0 at 24 months. Of the 54 eyes of 32 
patients, available for evaluation for a 12-month follow-up 
visit, all showed improvements in visual acuity by 2 lines 
or more. The delta logMAR was statistically significant 
during the first month (p < 0.001) and between 6 and 12 
months (p < 0.05) following treatment initiation (Fig. 2). 
Table 1. Orbital imaging measurements of 62 orbits with dysthyroid optic neuropathy
Apical crowding Size of extraocular muscle Intracranial fat prolapse
Grade No. of orbit (%) Muscle index (%) No. of orbit (%) No. of orbit (%)
0 00 (0) <50  00 (0)  15 (24.2)
1 03 (4.8)  >50  62 (100)
2 27 (43.5)  ≥67  28 (45.2)
3 32 (51.7) 
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Fig. 1. Best corrected decimal visual acuity of 65 eyes of 40 pa-
tients with dysthyroid optic neuropathy.
Table 2. Summary of treatment modalities in 39 patients with 
dysthyroid optic neuropathy
No. of patients (%)
IVMP 06 (15.4)
IVMP + radiation 17 (43.6)
IVMP + decompression 08 (20.5)
IVMP + decompression + radiation 08 (20.5)
Total 39 (100)
IVMP
 =
 intravenous methylprednisolone pulse therapy.76
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The patients were divided into a decompression group 
(26 eyes of 16 patients) and a non-decompression group (39 
eyes of 24 patients) (Fig. 3). While baseline logMAR visual 
acuity was 0.85 ± 0.70 in the decompression group and 0.38 
± 0.28 in the non-decompression group (p = 0.002), we 
noted no significant differences between the two groups 
after six months. Thus, orbital decompression achieved a 
greater improvement of vision than non-surgical treatment 
(p < 0.05). 
Recurrences occurred in 7 patients: 4 patients with 
IVMP therapy alone and 3 patients with IVMP and orbital 
decompression. None of the 20 patients who had received 
radiation therapy experienced a recurrence, compared with 
7 of the 14 patients treated without radiation therapy (p = 
0.001). It required a mean of 3.8 months (median 4 months; 
range, 1 to 7 months) to develop recurrent neuropathy fol-
lowing IVMP and/or orbital decompression. All of the pa-
tients who had a recurrence recovered fully after treatment 
with IVMP or radiation therapy. 
Discussion
DON is derived from thyroid orbitopathy, but is dif-
ferent in terms of its epidemiological features [1]. The 
complexity of DON and the variability of the presenting 
symptoms and signs of this condition present a challenge 
to clinicians who wish to develop a standardized clinical 
assessment [20]. As there are differences in the degree of 
thyroid orbitopathy and orbital anatomy between Cauca-
sians and Asians, we must evaluate the clinical profile and 
visual outcomes of Asian patients with DON. We assessed 
40 Korean patients treated for DON at the Samsung Medi-
cal Center between 1995 and 2007. Management was indi-
vidualized for each patient’s DON condition. 
Thyroid orbitopathy generally affects women in their 
fourth and fifth decades, the female-to-male ratio being 
approximately 4:1 [1]. Women are up to eight times more 
likely to evidence severe orbital involvement [10]. DON 
typically manifests when a person is between 40 and 80 
years old, and there is no prominent gender predilection; 
the female-to-male ratio has been reported as 1.6 to 2.4:1 
[3,4,20]. Patients with DON tend to be 8 to 11 years older 
at the time of examination than the patients without DON 
[3,4]. The sex ratio of our cases was almost 1:1, which cor-
responds to a higher incidence of DON in males than has 
been noted in previous studies. This indicates that males 
are much more likely to develop optic neuropathy than are 
female patients with thyroid orbitopathy, and that severe 
orbital involvement of thyroid disease does not necessarily 
result in neuropathy. We had no pediatric patients (un-
der the age of 18 years), as has also been the case in past 
reports [24-26]. It appears that patients younger than 20 
years old are not likely to evidence severe infiltration of 
the extraocular muscles.
Diabetes was noted in 25% of our cases, which supports 
the notion that vasculopathy is one of the pathogenetic fac-
tors of DON. Marginal oxygenation due to preexisting vas-
culopathy may make the optic nerve more susceptible to 
ischemic changes because of the compression [27]. Diabet-
ics are believed to suffer from a more impetuous and more 
recalcitrant course, and tend to evidence poorer final vi-
sual results [3,28]. Seven out of 10 diabetic patients in this 
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Fig. 3. Comparison of change in average visual acuity between 
the decompression group (26 eyes of 16 patients) and the non-
decompression group (39 eyes of 24 patients). logMAR = loga-
rithmically to the minimum angle of resolution.
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Fig. 2. Change of logarithmically to the minimum angle of reso-
lution (logMAR) visual acuity from time of diagnosis to 2 years 
after the start of treatment. Improvement of vision was statisti-
cally significant during the initial month (p < 0.001) and between 
6 and 12 months (p < 0.05) after the initiation of treatment.77
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study required decompressive surgery with poor response 
to corticosteroids, but they achieved the same final visual 
acuity as did the non-diabetics. Diabetes is a risk of DON, 
but it does not influence visual outcomes when neuropathy 
is treated appropriately. 
The symptoms of DON manifested at a median of 5.5 
months after the onset of eye symptoms of thyroid orbitop-
athy, with 5 cases of neuropathy developing with thyroid 
eye disease simultaneously. In the active inflammatory 
phase of thyroid orbitopathy, optic nerve compression by 
the retrobulbar tissue swelling renders optic neuropathy 
much more likely to occur. Decreased visual acuity was 
the most common complaint of our patients at the initial 
presentation. Pretreatment visual acuity was a median 
of 0.4, and the severity of visual loss was similar to that 
described in other reports [3,4,20]. Other chief complaints 
included aching ocular sensation, abnormal color percep-
tion, and visual field disturbances. Some patients did not 
even realize they were experiencing symptoms of optic 
nerve dysfunction. The authors suggest that careful history 
taking and thorough physical examination should be con-
ducted to detect this significant complication, particularly 
during the early inflammatory phase of thyroid orbitopa-
thy. 
Studies have demonstrated that computed tomography 
scanning provides objective measures that can be used to 
identify patients who have an increased risk of concurrent 
dysthyroid optic neuropathy [3,7,20-23]. MI, optic nerve 
crowding and intracranial fat prolapse were shown to be 
significantly related to the presence of DON in the litera-
ture, and thus were adopted as measures for the quantifica-
tion of optic nerve compression and orbital tissue volume 
increases in this study. 
Apical crowding has been reported to be a highly sen-
sitive and specific indicator of neuropathy [7,21,23]. We 
noted grade 2 and 3 apical crowding in 59 (95.2%) DON 
orbits. Grade 1 (mild) apical crowding was also noted in 3 
(4.8%) orbits, which clearly demonstrated clinical features 
of optic neuropathy and responded well to IVMP and ra-
diation therapy. In the absence of apical compression by 
pathologically enlarged extraocular muscles, increased 
orbital pressure may have induced DON [29]. With regard 
to the MI, it was previously reported that an MI <50% 
was able to exclude DON but an MI above 67% was not 
in unanimous agreement in excluding the negative cases 
[7,22]. Our data revealed that all DON orbits had an MI 
>50%, and approximately half of them had an MI >67%. 
It appears that an MI >50% is very sensitive for DON, and 
should be considered a risk for compressive optic neuropa-
thy. Intracranial fat prolapse was described as an indicator 
of DON with a sensitivity of 75% to 94% and a specificity 
of 52.9% to 91% [7,23]. We noted intracranial fat prolapse 
in only 24.2% of the cases, a similar rate to that noted in a 
recent study [20]. Therefore, it would appear to have less 
value in detecting DON on computed tomography than has 
been previously suggested. 
Moderate to severe apical crowding and an MI >50% are 
believed to be sensitive parameters indicating DON, but 
they cannot directly demonstrate the degree of optic nerve 
damage, such that their presence indicates optic nerve 
function tests and close observation are necessary for se-
lecting the optimal management strategy.
In the management of DON, we employed IVMP as the 
initial therapeutic trial. The intravenous route delivers a 
higher cumulative dose of corticosteroids with fewer side 
effects, and is considered to be more effective and better 
tolerated than the oral route [2,14]. Previous report re-
vealed improvement rates of 39% to 100%, and remissions 
were maintained with oral prednisone and orbital irradia-
tion [13,14,30]. Our results revealed that 23 (59.0%) patients 
were stabilized with non-surgical treatment, including 
corticosteroids and radiotherapy. Among these, six patients 
responded to corticosteroids and remained stable without 
additional therapy, and 17 patients required adjunctive 
radiation therapy. Sixteen (41.0%) patients received subse-
quent decompressive surgery as symptoms of DON did not 
improve or relapsed immediately after IVMP.
Patients in the surgery group evidenced significantly 
worse visual acuity at diagnosis than those in the non-sur-
gical group (logMAR 0.85 ± 0.70 vs. 0.38 ± 0.28). We can 
infer that patients with poor visual acuity are less inclined 
to respond to IVMP, and will require bony decompression. 
Patients in the surgery group evidenced rapid improve-
ment in optic nerve functions after decompression, and 
eventually attained a final visual acuity equal to that of 
the patients treated without decompression. This lends cre-
dence to two points: first, bony apex decompression is the 
most effective treatment for DON [19], and secondly, the 
delay of orbital decompression by first trying IVMP does 
not affect the ultimate visual function [30]. Although bony 
apex decompression continues to be a definitive treatment 
for DON [1,19,31-34], surgery may involve associated risks 
and may not be readily conducted in many medical facili-
ties. We believe that good assessments should be made and 
management should be individualized to induce maximal 
benefits, thus reducing associated harms. 
Radiotherapy is useful in actively inflamed orbits with 
optic nerve compression [1,5,10,15,16]. Combination ther-
apy with high-dose steroids proved more effective due to 
the rapid action of steroids during the short-term period 
and the more delayed (but sustained) action of radiation 
[14,31,32]. However, no studies thus far have assessed the 
effects of radiotherapy as the sole therapeutic modality for 
DON without adjunctive therapy, and some authors have 
denied its having beneficial therapeutic effects in thyroid 
orbitopathy [17,18]. It is our impression that radiotherapy 
alone does not affect improvements in optic nerve func-
tions, but its sustained anti-inflammatory effects prevent 78
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the recurrence of neuropathy following the immediate re-
covery of DON after treatment with IVMP or decompres-
sion surgery.
All of our patients evidenced improvement in visual 
acuity by two lines or more after treatment. Visual acuity 
evidenced marked improvement within one month after 
the onset of therapy, remained stable for five months, im-
proved again in the subsequent six months, and then stabi-
lized thereafter. Initial improvements in visual acuity are 
probably related to the relief of optic nerve compression in 
the orbital apex and reductions in optic nerve perfusion as 
the result of decompressive surgery and steroids. It appears 
unlikely that these two therapeutic modalities continue 
to be associated with improvement more than six months 
after treatment, as visual acuity remained stable for five 
months after immediate recovery. Radiotherapy appears 
not to affect the later recovery process directly, because 
visual acuity was the same whether or not the patients re-
ceived radiotherapy. Carter et al. [33] previously stated that 
eyes which required weeks to months prior to evidencing 
maximum recovery may have had more fibrotic ocular 
muscles or orbital tissue compressing the optic nerve. 
Later improvement of visual acuity may be explained by 
lessened thyroid eye disease activity and visual recovery 
following treatment for recurring neuropathy. 
Although we noted one patient whose reduced color vi-
sion and abnormal visual field returned to normal without 
specific treatment, the natural course of DON is difficult 
to predict, and is certainly not benign [1]. We have noted 
relatively good visual outcomes with adequately combined 
corticosteroid, radiotherapy and orbital decompression 
therapeutic modalities. Visual acuity continued to improve 
for up to one year after treatment. Physicians should seek 
individualized therapy, weighing the benefits and risks of 
each modality. After successful primary therapy, a close 
follow-up evaluation of the patient should be made when 
oral prednisone is tapered or discontinued, as recurrences 
may readily occur during this period. Radiotherapy can 
be routinely administered to all patients without contrain-
dications after the immediate recovery in order to reduce 
recurrence.
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